IST (ATG + CsA) — Competitive Intelligence Brief

IST (ATG + CsA) (IST (ATG + CsA)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressive combination therapy. Area: Immunology / Hematology-Oncology.

phase 3 Immunosuppressive combination therapy T lymphocytes (ATG); calcineurin (CsA) Immunology / Hematology-Oncology Small molecule

Target snapshot

IST (ATG + CsA) (IST (ATG + CsA)) — Federal Research Institute of Pediatric Hematology, Oncology and Immunology. IST combines anti-thymocyte globulin (ATG) and cyclosporine A (CsA) to suppress T-cell mediated immune responses and prevent graft rejection or autoimmune destruction.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
IST (ATG + CsA) TARGET	IST (ATG + CsA)	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	phase 3	Immunosuppressive combination therapy	T lymphocytes (ATG); calcineurin (CsA)
Sirolimus+MMF or MPS or AZA+Steroid	Sirolimus+MMF or MPS or AZA+Steroid	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	Immunosuppressive combination therapy	mTOR (sirolimus); IMPDH (MMF/MPS); purine synthesis (AZA); glucocorticoid receptor (steroid)
sirolimus, mycophenolat mofetil, fluvastatin	sirolimus, mycophenolat mofetil, fluvastatin	University Hospital Schleswig-Holstein	marketed	Immunosuppressive combination therapy with statin	mTOR, IMPDH, HMG-CoA reductase
Kidney transplant maintenance immunosuppression	Kidney transplant maintenance immunosuppression	Imperial College Healthcare NHS Trust	marketed	Immunosuppressive combination therapy
tacrolimus OD, mycophenolic acid, prednisolone	tacrolimus OD, mycophenolic acid, prednisolone	University Medical Center Groningen	marketed	Immunosuppressive combination therapy	Calcineurin (tacrolimus); IMPDH (mycophenolic acid); glucocorticoid receptor (prednisolone)
Cyclophosphamide, Azathioprine,prednisone,methylprednisolone	Cyclophosphamide, Azathioprine,prednisone,methylprednisolone	Assistance Publique - Hôpitaux de Paris	marketed	Immunosuppressive combination therapy
Zenapax®, CellCept® and prednisolone	Zenapax®, CellCept® and prednisolone	University of Oslo School of Pharmacy	marketed	Immunosuppressive combination therapy	IL-2 receptor (daclizumab); inosine monophosphate dehydrogenase (mycophenolate mofetil); glucocorticoid receptor (prednisolone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressive combination therapy class)

1. University Hospital, Brest · 2 drugs in this class
2. Pfizer · 2 drugs in this class
3. Fundação Pró Rim · 2 drugs in this class
4. Haukeland University Hospital · 1 drug in this class
5. Imperial College Healthcare NHS Trust · 1 drug in this class
6. Jinnah Postgraduate Medical Centre · 1 drug in this class
7. Novartis · 1 drug in this class
8. Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · 1 drug in this class
9. Swiss Cancer Institute · 1 drug in this class
10. University Hospital Freiburg · 1 drug in this class